News

Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET. Company Participants. Lucas Montarce - CFO Mike Czapar - SVP, IR. Confe ...
Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Zacks Investment Research on MSN8h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
MarketBeat on MSN9h
Is It Time to Buy the Dip in Novo Nordisk Stock?
CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
India Today13h
Tirzepatide outperforms semaglutide in clinical trial with faster weight loss
A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...
Fierce Pharma17h
Consumers remain averse to out-of-pocket GLP-1 costs: KPMG
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
BioPharma Dive22h
Novo to work with Septerna in hunt for oral obesity drugs
The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...